



23 April 2026
EMA/118426/2026
Press Office

Scientific advice and protocol assistance

Adopted during the CHMP meeting 20-23 April 2026.

Pre-authorisation: scientific advice and protocol assistance EMA centralised procedures

	1995-2025	2026	Overall total
Scientific Advice	7006	277	7283
Follow-up to Scientific Advice	2085	0	2085
Protocol Assistance	1528	58	1577
Follow-up to Protocol Assistance	766	0	766
EMA/EUnetHTA parallel consultation advice	165	0	165
Qualification of novel methodologies	264	7	271
	11814	343	12147

Outcome of the April 2026 CHMP meeting in relation to scientific advice procedures

Final scientific advice procedures

Substance	Intended indications	Type of request				Topic			
		New		Follow-up		Quality	Preclinical	Clinical	Significant benefit
		SA	PA	SA	PA				
Advanced Therapy	Treatment of AML	x				x		x	
Advanced Therapy	Treatment of Asherman's syndrome		x					x	
Advanced Therapy	Treatment of neuroblastoma	x				x	x	x	
Advanced Therapy	Treatment of acute myeloid leukaemia	x				x	x	x	

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Substance	Intended indications	Type of request				Topic			
		New		Follow-up		Quality	Preclinical	Clinical	Significant benefit
		SA	PA	SA	PA				
Advanced Therapy	Treatment of B-cell lymphoma	x						x	
Biological	Treatment of persistent BKV DNAemia	x				x	x	x	
Biological	Treatment of Immune thrombocytopenia	x						x	
Biological	Treatment of organ transplantation		x			x	x	x	
Biological	Treatment of Glanzmann thrombasthenia	x					x	x	
Biological	Treatment of LBCL	x						x	
Biological	Treatment of multiple system atrophy		x					x	
Biological	Treatment of pulmonary disease	x						x	
Biological	Treatment of Crohn's disease	x					x		
Biological	Treatment of Alzheimer's disease	x					x	x	
Biological	Treatment of atopic dermatitis	x				x		x	
Biological	Treatment of Ewing sarcoma	x						x	
Biological	Treatment of cancer	x						x	
Biological	Treatment of polyneuropathy	x						x	
Biological	Treatment of amyloidosis	x						x	
Biological	Treatment of NSCLC	x						x	
Biological	Treatment of cancer	x						x	
Biological	Treatment of intracerebral haemorrhage		x			x		x	x
Biological	Prevention of myocardial infarction	x					x	x	
Biological	Treatment of early Alzheimer's disease	x				x	x	x	
Biological	Treatment of Alzheimer's disease	x				x		x	
Biological	Treatment of Crohn's disease	x					x	x	
Biological	Treatment of Multiple sclerosis	x					x	x	
Biological	Treatment of multiple myeloma	x						x	
Biological	Treatment of peritoneal cancer	x						x	
Biological	Treatment of Type 2 diabetes mellitus	x						x	

Substance	Intended indications	Type of request				Topic			
		New		Follow-up		Quality	Preclinical	Clinical	Significant benefit
		SA	PA	SA	PA				
Biological	Treatment of endometrial cancer	x				x			
Biological	Treatment of Crohn's disease	x				x			
Biological	Treatment of IDS	x						x	
Biological	Diagnosis of tuberculosis infection	x				x	x	x	
Biological	Prevention of COVID-19	x				x			
Biological	Prevention of yellow fever							x	
Biological	Prevention of food allergy	x						x	
Biological	Treatment of rheumatoid arthritis	x				x		x	
Biological	Treatment of rheumatoid arthritis	x				x		x	
Biological	Treatment of multiple myeloma	x				x		x	
Biological	Treatment of Crohn's disease	x				x		x	
Biological	Treatment of cancer	x				x	x	x	
Biological	Treatment of thrombocytopenia	x				x		x	
Biological	Treatment of ulcerative colitis	x				x		x	
Biological	Treatment of paediatric high-risk malignancies	x						x	
Chemical	Treatment of asthma	x					x		
Chemical	Treatment of eye disorder	x				x		x	
Chemical	Treatment of asthma	x				x		x	
Chemical	Treatment of depressive disorder	x					x	x	
Chemical	Treatment of Ulcerative colitis	x						x	
Chemical	Treatment of Psoriasis	x						x	
Chemical	Treatment of primary biliary cholangitis		x					x	
Chemical	Treatment of sickle cell disease		x				x	x	
Chemical	Treatment of KCNT1-related epilepsy	x					x	x	
Chemical	Treatment of tumours	x					x		

Substance	Intended indications	Type of request				Topic			
		New		Follow-up		Quality	Preclinical	Clinical	Significant benefit
		SA	PA	SA	PA				
Chemical	Treatment of hypercholesterolaemia	x					x	x	
Chemical	Treatment of actinic keratosis lesions	x				x		x	
Chemical	Treatment of weight maintenance	x					x	x	
Chemical	Treatment of adenocarcinoma		x					x	x
Chemical	Treatment of COPD	x						x	
Chemical	Treatment of polycythaemia vera		x				x	x	
Chemical	Treatment of Systemic Lupus Erythematosus	x					x	x	
Chemical	Treatment of weight maintenance	x		x					
Chemical	Treatment of depression	x				x	x	x	
Chemical	Treatment of Alzheimer's Disease	x					x		
Chemical	Treatment of myelofibrosis	x						x	
Chemical	Treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis	x					x	x	
Chemical	Treatment of inherited retinal dystrophies	x				x	x	x	
Chemical	Treatment of obesity	x					x	x	
Chemical	Treatment of Moderate Alopecia areata	x						x	
Chemical	Treatment of multiple myeloma	x						x	
Chemical	Treatment of blood disease	x				x	x	x	
Chemical	Treatment of epilepsy	x					x		
Chemical	Treatment of metastatic pancreatic adenocarcinoma	x					x	x	
Chemical	Treatment of Pulmonary tuberculosis	x					x	x	
Chemical	Treatment of tuberculosis		x			x	x		

SA: Scientific Advice
PA: Protocol Assistance

The above-mentioned 76 Scientific Advice letters – 67 Initial Scientific Advice, 9 Protocol Assistance letters, 0 Qualifications of novel methodologies and 0 EMA/EUnetHTA parallel consultation advice were adopted at the 20-23 April 2026.

New requests for scientific advice procedures

The Committee accepted 89 new Requests for which the procedure started at the SAWP meeting held on 7 - 9 April 2026. The new requests are divided into as follows: 73 Initial Scientific Advice, 15 Protocol Assistance letters, 1 Qualifications of novel methodologies and 0 EMA/EUnetHTA parallel consultation advice.